Ovid Therapeutics Inc. (1OT)

Overview

Ovid Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and delivering impactful medicines for patients and families affected by epilepsies and seizure-related neurological disorders. Founded in 2014 and headquartered in New York, New York, Ovid Therapeutics has positioned itself as a trailblazer in the treatment of resistant epilepsies and other seizure-related conditions. The company's formidable dedication to addressing unmet medical needs in neurology through innovative therapeutic approaches is underscored by its collaborative efforts with leading medical institutions and pharmaceutical companies including Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, Graviton, and Marinus Pharmaceuticals, Inc. This extensive network of collaborations enhances Ovid's research capacity and accelerates the development of its novel therapeutic solutions, bringing hope to patients and families grappling with these challenging conditions.

Products and Services

• Soticlestat (TAK-935/OV935)

  A pioneering cholesterol 24 hydroxylase inhibitor, soticlestat is at the forefront of Ovid's pipeline, currently in Phase 3 clinical trials. Its development aims to provide a novel treatment option for patients with resistant epilepsies, demonstrating Ovid's commitment to addressing the needs of individuals with limited therapeutic options.

• OV329

  An emerging therapy, OV329 is a GABA aminotransferase inhibitor now in Phase 1 clinical trials. This therapeutic candidate targets seizures associated with tuberous sclerosis complex and infantile spasms, reflecting Ovid's focus on seizure-related disorders and its commitment to expanding treatment modalities for these conditions.

• OV350

  OV350, a novel small molecule direct activator of the KCC2 transporter, is in Phase 1 clinical trials. This innovative approach aims to treat various epilepsies, showcasing Ovid Therapeutics' continuous pursuit of breakthrough treatments in neurology.

• OV815

  This program targets mutations associated with KIF1A-associated neurological disorder (KAND), reflecting Ovid's dedication to developing treatments for rare neurological disorders. OV815 exemplifies the company's strategy to identify and advance therapies for conditions with high unmet medical need.

• OV888 (GV101)

  A highly selective rock2 inhibitor, OV888 is currently in a Phase 1 double-blind multiple-ascending dose trial. This underscores Ovid's commitment to exploring novel pathways and mechanisms for the treatment of neurological disorders.

• OV825

  Ovid is advancing OV825 as a potential candidate for treating the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome). This effort reflects the company's focus on addressing gaps in care for rare and underserved neurological conditions.

• OV882

  OV882 is a short hairpin RNA gene therapy candidate for the treatment of Angelman syndrome, a genetic disorder that affects the nervous system. By developing OV882, Ovid Therapeutics showcases its innovative approach to gene therapy as a mechanism to address neurological disorders at their genetic roots.